TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 373560
Drug: Administration sets
Normalized name: administration sets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration sets changed every 48 hours
Study: 30037647
Drug: Antibiotic prophylaxis
Normalized name: STONE PROPHYLAXIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic prophylaxis once daily for 12 months
Study: 20178563
Drug: Atorvastatin 40
Normalized name: atorvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 40 mg daily for 8 weeks and 10 mg for the next 4 months (AF group)
Study: 20178563
Drug: Atorvastatin 40
Normalized name: atorvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 40 mg daily for 8 weeks and 10 mg for the next 4 months (non-AF group)
Study: 17503876
Drug: Exercise training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise training and supplements (oxygen, oral creatine, anabolic steroids and polyunsaturated fatty acids)
Study: 16037110
Drug: Sublingual misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual misoprostol 400 mg every 3 h for a maximum of five doses
Study: 16037110
Drug: Oral misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral misoprostol 400 mg every 3 h for a maximum of five doses
Study: 7748753
Drug: Terbinafine 250
Normalized name: terbinafine 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbinafine 250 mg/day for 2 weeks
Study: 7748753
Drug: Itraconazole 100
Normalized name: itraconazole 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole 100 mg/day for 4 weeks
Study: 24427672
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate 200 mcg/day plus oral Levocetirizine 5 mg/day (n: 21)
Study: 24427672
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate 200 mcg/day plus oral Montelukast 10 mg/day (n: 21)
Study: 24427672
Drug: Topical Mometasone
Normalized name: mometasone Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Mometasone furoate 200 mcg/day (n: 14)
Study: 21088253
Drug: Atazanavir treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atazanavir treatment (3-day duration)
Study: 18440147
Drug: 40% menthol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40% menthol solution
Study: 18440147
Drug: 20% cinnamaldehyde
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% cinnamaldehyde solution
Study: 16848645
Drug: Bupropion XL
Normalized name: Bupropion Hydrochloride 150 MG Oral Tablet, Extended Release [BUPROPION XL]
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupropion XL 300 to 450 mg/day
Study: 14572572
Drug: Mesalamine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesalamine (4 g o.d.)
Study: 10846036
Drug: n-3 fatty
Normalized name: n-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 fatty acid supplementation at 4 g/day
Study: 10846036
Drug: Control trial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control trial (fat meal, 100 g fat)
Study: 2878747
Drug: SMS 201-995,
Approvals — FDA: no, EMA: no, PMDA: no
Description: SMS 201-995, 50 micrograms, twice daily subcutaneous injection
Study: 30373463
Drug: DREAMS:START intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: DREAMS:START intervention to improve sleep for people living with dementia; details on dosage and duration not specified.
Study: 27274151
Drug: Herbal oral
Normalized name: Sucrets Herbal Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal oral rinse
Study: 22944595
Drug: Twelve Step
Normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Twelve Step Facilitation (TSF) treatment
Study: 20965928
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg erythromycin once daily for 12 weeks
Study: 6425917
Drug: Standard tricyclic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard tricyclic antidepressants
Study: 30852547
Drug: Ticagrelor monotherapy
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor monotherapy (90 mg twice daily) after 1-month DAPT
Study: 30852547
Drug: Standard regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard regimen of DAPT for 12 months followed by aspirin monotherapy
Study: 28884877
Drug: Self-administered acupressure
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administered acupressure (n=15)
Study: 16225499
Drug: Nifuratel (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifuratel (15 mg/kg/day, q.d.s.)
Study: 16225499
Drug: Furazolidone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furazolidone (10 mg/kg/day, q.d.s.)
Study: 8527292
Drug: MK-0476 20
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-0476 20 to 800 mg single oral doses
Study: 8527292
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg MK-0476 as a solution
Study: 8527292
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg MK-0476 capsules after a standard breakfast
Study: 1526087
Drug: Aspirin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (100 mg/ml) in methyl cellulose gel
Study: 28924018
Drug: Ibrutinib (420
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibrutinib (420 mg daily)
Study: 20090348
Drug: Thermoreversible wound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thermoreversible wound gel containing polyhexanide
Study: 18362418
Drug: Aggressive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive therapy aiming for targets of <120/80 mmHg and <80 mg/dl for blood pressure and LDL-C respectively.
Study: 18362418
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy aiming for blood pressure <140/90 mmHg and LDL-C <100 mg/dl.
Study: 31462727
Drug: Soursop supplementation
Normalized name: soursop extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soursop supplementation (2 × 100 g soursop fruit juice per day for 3 months)
Study: 29454333
Drug: Ultrasound-guided paravertebral
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided paravertebral block (PVB) with 0.5% bupivacaine, 15 mL
Study: 29454333
Drug: Intravenous tramadol,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous tramadol, loading dose of 1 mg/kg
Study: 26440201
Drug: Ti implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ti implants (4.1 mm diameter)
Study: 26440201
Drug: Ti‐Zr implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ti‐Zr implants (3.3 mm diameter)
Study: 26440201
Drug: Both Ti
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both Ti and Ti‐Zr implants
Study: 24163236
Drug: Monthly telephone
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly telephone counselling (control)
Study: 18179556
Drug: IL-6 at
Normalized name: IL-6
DrugBank: Human interleukin-6 (DB15060)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL-6 at cut-off of 125 pg/ml
Study: 12702979
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy with rabeprazole, clarithromycin, and tinidazole plus lactoferrin for 7 days (group A)
Study: 12702979
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy with rabeprazole, clarithromycin, and tinidazole for 7 days (group B)
Study: 12702979
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy with rabeprazole, clarithromycin, and tinidazole for 10 days (group C)
Study: 9411221
Drug: Antiarrhythmic-drug therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiarrhythmic-drug therapy (primarily amiodarone)
Study: 8377779
Drug: 5,6-benzo-[alpha]-pyrone (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5,6-benzo-[alpha]-pyrone (400 mg for six months)
Study: 2439814
Drug: bopindolol 2
Normalized name: bopindolol
DrugBank: Bopindolol (DB08807)
Approvals — FDA: no, EMA: no, PMDA: no
Description: bopindolol 2 mg
Study: 24880197
Drug: Cognitive functioning
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive functioning and physical capacity assessed after 13 weeks of CRC supplementation (2.5 g per day of chicken meat extract containing 40% CRC components).
Study: 22644963
Drug: Besifloxacin ophthalmic
Normalized name: besifloxacin ophthalmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Besifloxacin ophthalmic suspension 0.6% dosed twice daily
Study: 20427668
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of prednisolone (synthetic mixed glucocorticoid/mineralocorticoid agonist)
Study: 20427668
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of prednisolone
Study: 20427668
Drug: Glucocorticoid receptor
Normalized name: Glucocorticoid receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucocorticoid receptor antagonist pretreatment
Study: 12598380
Drug: Heptavalent pneumococcal
Normalized name: botulinum neurotoxin B immune FAB2
DrugBank: Equine Botulinum Neurotoxin B Immune FAB2 (DB13903)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heptavalent pneumococcal conjugate vaccine (7VPnCV)
Study: 10696418
Drug: Artesunate plus
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Artesunate plus sulfadoxine-pyrimethamine (4 mg/kg for 3 days and 25 mg/kg sulfadoxine)
Study: 8738856
Drug: Intact and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intact and dispersed josamycin Solutab tablet (1,000 mg)
Study: 8738856
Drug: Josacine reference
Approvals — FDA: no, EMA: no, PMDA: no
Description: Josacine reference sachet (1,000 mg)
Study: 19839170
Drug: Group A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A: 50 J/cm2/100 J/cm3 (laser/RF), two passes, three treatment sessions 30 days apart
Study: 19839170
Drug: Group B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B: 30 J/cm2/50 J/cm3, three passes, five treatment sessions 15 days apart
Study: 17590966
Drug: Structured music
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured music therapy groups
Study: 6380179
Drug: 0.4 g
Normalized name: psyllium 0.4 GM Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 g of doxycycline preoperatively
Study: 6380179
Drug: 0.2 g
Normalized name: methionine 0.2 gram ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 g of doxycycline preoperatively and 0.1 g of doxycycline on the first, second and third postoperative day
Study: 28081952
Drug: Alteplase (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alteplase (1 mg, up to 12 doses, 8 h apart via extraventricular drain)
Study: 28081952
Drug: Saline (0.9%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (0.9% saline, up to 12 doses, 8 h apart via extraventricular drain)
Study: 26585569
Drug: Weekly GMA
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly GMA (one session per week)
Study: 12639367
Drug: Fluoxetine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (20 mg/day) plus tibolone (2.5 mg/day)
Study: 1400054
Drug: Fluid Replacement
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluid Replacement (FR) - carbohydrate-electrolyte fluid replacement solution sufficient to replace 80 ± 2% of sweat loss
Study: 1400054
Drug: Blood Volume
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood Volume Expander (BVX) - 5.3 ml/kg of 6% dextran in saline
Study: 2862419
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg vitamin K administered at birth
Study: 2862419
Drug: Untreated group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Untreated group (no vitamin K administration)
Study: 2862419
Drug: Vitamin K
Normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K administered to newborns with normotest levels < 30%
Study: 20389176
Drug: 4-liter PEG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-liter PEG solution plus magnesium hydroxide
Study: 20389176
Drug: 4-liter PEG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-liter PEG solution
Study: 19277245
Drug: Omega-3 dietary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 dietary supplementation (two 1000-mg capsules 3 times a day)
Study: 14624169
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg vitamin C, 800 mg vitamin E, 10 mg folic acid
Study: 10760722
Drug: IAN +
Normalized name: Gentian + sodium bicarbonate
Approvals — FDA: no, EMA: no, PMDA: no
Description: IAN + IO injection with 1.8 mL of 1.5% etidocaine hydrochloride containing 1:200,000 epinephrine
Study: 10760722
Drug: IAN +
Normalized name: Gentian + sodium bicarbonate
Approvals — FDA: no, EMA: no, PMDA: no
Description: IAN + mock IO injection
Study: 10760722
Drug: IO injection
Normalized name: Io-Shield
Approvals — FDA: no, EMA: no, PMDA: no
Description: IO injection of etidocaine hydrochloride
Study: 6469079
Drug: Lactose containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactose containing diet (LC diet) - 150 g/d, high protein (112 g/d)
Study: 6469079
Drug: Lactose free
Normalized name: Similac Lactose Free
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactose free diet (LF diet) - normal protein (67 g/d)
Study: 30758744
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg ASA/200 mg paracetamol/50 mg caffeine (test)
Study: 30758744
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg ASA/200 mg paracetamol (reference)
Study: 25427964
Drug: Implants with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implants with a screwed tapered internal connection placed subcrestally (Group 1)
Study: 25427964
Drug: Implants with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implants with a screwed tapered internal connection placed crestally (Group 2)
Study: 25427964
Drug: Implants with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implants with an internal conical seal connection placed subcrestally (Group 3)
Study: 25427964
Drug: Implants with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implants with an internal conical seal connection placed crestally (Group 4)
Study: 15957832
Drug: Qinggan Jiangtang
Normalized name: Jianghuang
DrugBank: Turmeric (DB14276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qinggan Jiangtang tablet (QJT) 3 tabs, twice a day for 1 month
Study: 15957832
Drug: Glucophage 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucophage 3 tabs, twice a day for 1 month
Study: 10431273
Drug: iodixanol 320
Normalized name: IODIXANOL 320mgI/ml INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: iodixanol 320 mgl/ml
Study: 10431273
Drug: ioxaglate 320
Normalized name: ioxaglate
Approvals — FDA: no, EMA: no, PMDA: no
Description: ioxaglate 320 mgl/ml
Study: 7589030
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA, 1.0 g)
Study: 7589030
Drug: Ibuprofen (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (0.8 g)
Study: 7589030
Drug: Paracetamol (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol (1.0 g)
Study: 2209678
Drug: Cyclosporine A
Normalized name: CycloSPORINE A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine A (CYA) 5 mg/kg/day
Study: 28181639
Drug: Withdrawal of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withdrawal of fall‐risk‐increasing‐drugs (FRIDs)
Study: 25319761
Drug: ethinyl estradiol
Normalized name: Ethinyl Estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ethinyl estradiol (EE) 30 mcg/desogestrel 150 mcg plus spironolactone 25 mg/day (group A)
Study: 25319761
Drug: ethinyl estradiol
Normalized name: Ethinyl Estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ethinyl estradiol (EE) 35 mcg/cyproterone acetate 2 mg (group B)
Study: 23820059
Drug: Dutasteride 0.5
Normalized name: dutasteride 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dutasteride 0.5 mg per day
Study: 19586937
Drug: Rituximab added
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab added to dose-dense and high-dose chemotherapy (R-MegaCEOP14, R-MAD, BEAM) with autologous stem cell transplantation
Study: 19586937
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy without rituximab (MACOP-B, MAD, BEAM)
Study: 17721968
Drug: Behaviorally intensive,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behaviorally intensive, contingency management treatment
Study: 17721968
Drug: Less-intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Less-intensive treatment
Study: 14756849
Drug: Zolmitriptan (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolmitriptan (2.5 mg or 5 mg based on migraine severity)
Study: 11790416
Drug: Breakfast of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breakfast of 10 or 50 g of carbohydrate (corn flakes)
Study: 11790416
Drug: Snack of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Snack of 25 g of carbohydrate (corn flakes) after 1 1/2 h
Study: 7978128
Drug: Three vital
Normalized name: Vital-Chlor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three vital capacity breaths of room air during intravenous propofol administration (2.5 mg.kg‐1)
Study: 2688586
Drug: Intravenous nicardipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous nicardipine hydrochloride
Study: 2688586
Drug: Subsequent treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subsequent treatment with nicardipine after placebo failure
Study: 1081271
Drug: Calcium (2
Normalized name: calcium (2ξ)-D-gluco-heptonate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium (2 g per day)
Study: 31287199
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (mechanical diagnosis therapy and transforaminal epidural steroid injections)
Study: 31648781
Drug: Experimental antiplatelet
Normalized name: simethicone
DrugBank: Simethicone (DB09512)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental antiplatelet treatment strategy
Study: 31648781
Drug: Reference antiplatelet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference antiplatelet treatment strategy
Study: 22712537
Drug: Ranibizumab (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranibizumab (0.5 mg in 0.05 mL) administered intravitreally at three time points: 9 days prior to surgery, 1 month post-surgery, and 2 months post-surgery.
Study: 19263591
Drug: Calcium plus
Normalized name: O Calcium Plus D
DrugBank: Cupric oxide (DB11134)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium plus vitamin D supplementation (600 mg elemental calcium and 5 microg vitamin D, consumed twice a day)
Study: 7700070
Drug: cilazapril 2.5‐5
Approvals — FDA: no, EMA: no, PMDA: no
Description: cilazapril 2.5‐5 mg daily for 6 months
Study: 3662594
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of human growth hormone (hGH)
Study: 3662594
Drug: Pulsatile treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsatile treatment with human growth hormone (hGH)
Study: 3662594
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment with human growth hormone (hGH)
Study: 29691197
Drug: Motivational Intervention‐Medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motivational Intervention‐Medication Therapy Management (MI‐MTM)
Study: 15870721
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid (4 mg) administered in the community setting
Study: 15870721
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid (4 mg) administered in the hospital setting
Study: 11100343
Drug: Somatostatin 250
Normalized name: Somatostatine
DrugBank: Somatostatin (DB09099)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatostatin 250 mcg i.v. bolus followed by continuous i.v. infusion at a rate of 6 mg/d for 72 h
Study: 11100343
Drug: Ranitidine 300
Normalized name: ranitidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 300 mg/d by continuous i.v. infusion for 72 h
Study: 9581001
Drug: Twelve-Step Facilitation
Normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Twelve-Step Facilitation Therapy (TSF)
Study: 3529884
Drug: Aspirin +
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin + Diclofenac
Study: 29573375
Drug: 4% articaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% articaine with buccal intrapapillary infiltration
Study: 29573375
Drug: 2% lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% lidocaine with inferior dental nerve block and long buccal infiltration
Study: 24404799
Drug: Daily preventive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily preventive asthma medication prescribed (current prescription)
Study: 16548349
Drug: Wuling pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wuling pill (WLP) plus conventional therapy
Study: 9006746
Drug: Placebo (oral,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (oral, twice daily on days 2-6)